RICE ORS WITH HIV ASSOCIATED DIARRHEA

与 HIV 相关的腹泻的大米或其他药物

• 批准号: 2017590
• 负责人: DAVID A SACK
• 金额: $ 4.86万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-02-01 至 1999-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2017590
• 关键词: AIDS therapy; HIV infections; adult human (21+); body fluid balance therapy; body water dehydration; body weight; clinical research; clinical trials; diarrhea; diet therapy; food science /technology; human subject; human therapy evaluation; intravenous administration; nutrition related tag; opportunistic infections; oral administration; outcomes research; rice; secondary infection

DESCRIPTION (Taken from application) The long term goal is to maximize the appropriate use of oral rehydration therapy as a simple and inexpensive treatment for dehydration in adults with HIV-associated diarrhea. Using rice-based oral rehydration solution (RB-ORS), dehydrated patients with HIV-associated diarrhea should be able to replace fluids, maintain hydration and electrolyte balance and thereby a) lessen the need for hospitalization and intravenous fluids, b) increase the ability of the patients to live independently, c) lessen diarrhea-associated morbidity by decreasing the volume and duration of purging. Specifically, the study should show a) that RB-ORS will effectively rehydrate and maintain hydration in most HIV infected adults with diarrhea, b) that the rehydration treatment with RB-ORS will have no untoward effects, and c) that patients will prefer RB-ORS as a means of rehydration compared to I.V. treatment. This will be a randomized clinical trial of 30 patients with HIV-associated diarrhea who are felt to require intravenous fluids by their physician because of objective signs of dehydration. They will be randomized to receive either RB-ORS (n=20) or intravenous rehydration (n=10), and they will receive this treatment while being monitored in Johns Hopkins Hospital General Clinical Research Center for two days. Using objective measures of rehydration (body weight, fluid intake and output, serial hematocrit and total protein measurements, and serial bioimpedence), the success rate and the rate of improvement with the two treatments will be documented. Patients who receive RB- ORS but are not rehydrated will be placed on I.V.'s. If a high proportion of the patients can be successfully rehydrated and maintained with RB-ORS, the usefulness of RB-ORS will be established.

描述（摘自申请） 长期目标是最大限度地适当使用口服补液 疗法作为成人脱水的一种简单且廉价的治疗方法 艾滋病毒相关腹泻。 使用大米口服补液 (RB-ORS)，患有 HIV 相关腹泻的脱水患者应该能够 补充液体，维持水合作用和电解质平衡，从而a) 减少住院和静脉输液的需要，b) 增加 患者独立生活的能力，c) 减少腹泻相关的 通过减少净化量和持续时间来降低发病率。 具体来说， 研究应表明 a) RB-ORS 将有效地补充水分并维持 大多数患有腹泻的 HIV 感染成人需要补充水分，b) 补充水分 RB-ORS 治疗不会产生不良影响，并且 c) 患者 与 I.V. 相比，会更喜欢 RB-ORS 作为补液方式。治疗。 这是一项针对 30 名 HIV 相关患者的随机临床试验 医生认为需要静脉输液的腹泻者 因为客观的脱水迹象。 他们将被随机分配到 接受 RB-ORS (n=20) 或静脉补液 (n=10)，并且他们 将在约翰·霍普金斯医院接受监测的同时接受这种治疗 一般临床研究中心为期两天。 使用客观措施 补液（体重、液体摄入量和排出量、系列血细胞比容和 总蛋白测量和系列生物阻抗），成功率和 将记录两种治疗的改善率。 接受 RB-ORS 但未补液的患者将被置于 静脉注射。如果大部分患者能够成功补液 并通过 RB-ORS 进行维护，RB-ORS 的有效性将被确定。